-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor
Recently, Relay Therapeutics announced positive interim data
Cholangiocarcinoma is a rare malignancy that can be divided into intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma
RLY-4008 is the development of a specific inhibitor
Patients enrolled in the ReFocus trial have advanced solid tumors whose FGFR2 gene fusion/rearrangement is confirmed
Image credit: 123RF
As of 1 August this year, efficacy data were included in 38 patients with cholangiocarcinoma who had been previously treated with FGFR2 fusion/rearrangement and had not previously received FGFR inhibitors
Among patients receiving all doses (N=195), the most common treatment-related adverse effects (TRAE) were low-grade stomatitis (48%), acromegaly (46%), and dry mouth (31%)
According to the published summary, RLY-4008 is a promising next-generation inhibitor that could revolutionize the treatment of patients with bile duct cancer who have not previously received FGFR inhibitor therapy
WuXi AppTec provides integrated, end-to-end new drug development and production services to the global biopharmaceutical industry, covering chemical drug development and production, biological research, preclinical and clinical trial development, cell and gene therapy research and development, testing and production
.
If you have relevant business needs, please click on the image below to fill in the specific information
.